CARLSBAD, Calif., Nov. 5, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ:TYRA). Such investors are advised to
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ:TYRA). Such investors are advised
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ:TYRA). Such investors are advised to
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ:TYRA). Such investors are advised
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ:TYRA). Such investors are advised
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ:TYRA). Such investors are advised to
TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBCFavorable safety and tolerability results support chronic dosing potentialNo clinically significant
CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in
CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in
- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer-CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc.
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH -- First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 -- Initial
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in
